脑膜炎败血伊丽莎白菌(Elizabethkingia meningoseptica, EM)可引起肺部感染、新生儿脑膜炎、菌血症等疾病，医院重症监护病房检出率较高，是院内感染的重要病原体之一。随着抗菌药物的广泛使用，EM对β-内酰胺类、氨基糖苷类、氟喹诺酮类等临床常用抗菌药物呈多重耐药，给临床治疗带来极大困难。目前EM的耐药机制研究主要集中于产生药物灭活酶、药物作用靶位改变、外排泵、形成生物膜等方面。EM可同时携带多个耐药基因，如GOB、BlaB、CME等，从而介导多重耐药。本文就国内外EM耐药现状、耐药机制进行综述，旨在为预防和控制EM的医院内感染提供参考。

Elizabethkingia meningosepticum (EM), which causes nosocomial pneumonia, neonatal meningitis, bacteremia and other diseases, is one of the most important pathogens of nosocomial infections. In recent years, the detection rate of EM in the intensive care unit (ICU) has shown an upward trend. Due to the widespread use of antibiotics, EM is multi-drug resistant to commonly used clinical antibiotics such as β-lactams, aminoglycosides and fluoroquinolone, which brings great difficulties to clinical treatment. At present, researches on EM resistance mechanisms in different countries mainly include the production of drug-inactivating enzymes, changes in drug targets, and the formation of biofilms. EM has multiple drug-resistant genes such as GOB, BLaB, CME, which mediate their multiple resistance. This article reviewed the drug resistance and resistance mechanism of EM, hoped to provide references for the prevention and control of nosocomial infections of EM.